Breast cancer remains a major global health concern, contributing substantially to cancer-related morbidity and mortality among women. Despite advances in treatment, challenges such as drug resistance, systemic toxicity, and disease recurrence highlight the need for novel therapeutic agents. Cinnoline derivatives have emerged as promising anti-cancer compounds due to their diverse pharmacological properties. These heterocyclic molecules exert potent antiproliferative effects through multiple mechanisms, including induction of apoptosis, cell cycle arrest, and inhibition of oncogenic signaling pathways such as PI3K/Akt/mTOR and MAPK. Moreover, cinnoline derivatives show potential in overcoming drug resistance by modulat-ing efflux transporters and targeting cancer stem cells. Their pharmacokinetic profile—including absorption, distribution, metabolism, and excretion (ADME)—critically influ-ences clinical viability. Challenges such as poor solubility, rapid metabolism, and ineffi-cient absorption limit oral bioavailability, while lipophilicity and CYP450-mediated me-tabolism affect drug half-life, clearance, and overall therapeutic performance. Recent advancements in drug delivery strategies have improved the bioavailability and therapeutic index of cinnoline derivatives. Nanocarrier-based systems, including liposomes and polymeric nanoparticles, enable targeted delivery, minimizing systemic toxicity while enhancing efficacy. Additionally, cinnoline derivatives have demonstrated synergistic ef-fects when combined with conventional chemotherapeutics, immunotherapies, and hor-mone-based treatments, providing promising avenues for combination therapy. Nevertheless, optimizing pharmacokinetics, reducing off-target toxicity, and ensuring clin-ical translation remain significant challenges. Future research should focus on structural modifications, personalized medicine approaches, and rigorous preclinical and clinical evaluations to validate safety and efficacy. Overall, cinnoline derivatives hold substantial potential to revolutionize breast cancer therapy, offering more precise, effective, and well-tolerated treatment options.
Sreenivasan et al. (Fri,) studied this question.